# Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions

> **NCT06371716** · NA · TERMINATED · sponsor: **IRCCS San Raffaele** · enrollment: 45 (actual)

## Conditions studied

- Pancreatic Cancer
- Endoscopic Ultrasound
- Radiofrequency Ablation

## Interventions

- **PROCEDURE:** ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
- **PROCEDURE:** ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
- **PROCEDURE:** ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions

## Key facts

- **NCT ID:** NCT06371716
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-12
- **Primary completion:** 2020-06-12
- **Final completion:** 2020-06-12
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** resectable pancreatic adenocarcinoma and neuroendocrine pancreatic neoplasms are difficult to be enrolled. Pancreatic resectable cancers are treated nowadays with chemotherapy and big neuroedocrine pancreatic lesions rare
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06371716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06371716, "Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06371716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*